CHA
AXSM icon

Carmichael Hill & Associates’s Axsome Therapeutics AXSM Stock Holding History

Carmichael Hill & Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$9K – 790
2022
Q3 		$9K Hold
200
– – ﹤0.01% 580
2022
Q2 		$8K Hold
200
– – ﹤0.01% 590
2022
Q1 		$8K Buy
200
+100
+100% +$3.1K ﹤0.01% 625
2021
Q4 		$4K Hold
100
– – ﹤0.01% 717
2021
Q3 		$3K Sell
100
-200
-67% -$7.79K ﹤0.01% 723
2021
Q2 		$20K Buy
300
+50
+20% +$3K 0.01% 515
2021
Q1 		$14K Hold
250
– – 0.01% 541
2020
Q4 		$20K Hold
250
– – 0.01% 467
2020
Q3 		$18K Hold
250
– – 0.01% 441
2020
Q2 		$21K Sell
250
-250
-50% -$19.2K 0.02% 403
2020
Q1 		$29K Sell
500
-300
-38% -$24.4K 0.03% 329
2019
Q4 		$83K Buy
+800
New +$32.3K 0.06% 217

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Carmichael Hill & Associates's AXSM Position: Q4 2022 in Review

Carmichael Hill & Associates sold out of Axsome Therapeutics (AXSM) in Q4 2022, closing a stake of 200 shares — an estimated $9K sold.

Carmichael Hill & Associates first reported a position in AXSM in Q4 2019 and held it in 12 quarters. The position peaked at $83K in Q4 2019. 219 funds tracked by Wall St. Rank hold AXSM as of Q4 2022.

  • Carmichael Hill & Associates reported no remaining Axsome Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Carmichael Hill & Associates sold 200 Axsome Therapeutics shares in Q4 2022, an estimated $9K.
  • Carmichael Hill & Associates first reported a position in Axsome Therapeutics in Q4 2019 and held it in 12 quarters.
  • Carmichael Hill & Associates's Axsome Therapeutics position peaked at $83K in Q4 2019.
  • 219 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2022.

Based on Carmichael Hill & Associates's 13F filing for Q4 2022, filed 14 Feb 2023.